ACE2 and COVID-19: Studies reporting increased ACE2 expression with angiotensin (Ang)-converting enzyme-1 (ACE-1) inhibitors (ACEIs) and Ang type 1 receptor (AT1R) antagonists (ARBs) [2,3,4,5] suggested that renin-angiotensin system (RAS) blockers could worsen the prognosis of COVID-19 patients [6,7].